

**Medicine summary -trimipramine (to end January 2009)**

			Case Group	Death Outcomes	Sole
Case Count			70	2	33
Reaction Count	Blood and lymphatic system disorders	Anaemia	1	0	0
		Pancytopenia	1	0	0
		Haemolytic anaemia	1	0	0
		<b>Blood and lymphatic system disorders</b>	<b>3</b>	<b>0</b>	<b>0</b>
	Cardiac disorders	Tachycardia	2	0	1
		<b>Cardiac disorders</b>	<b>2</b>	<b>0</b>	<b>1</b>
	Ear and labyrinth disorders	Vertigo	1	0	0
		<b>Ear and labyrinth disorders</b>	<b>1</b>	<b>0</b>	<b>0</b>
	Eye disorders	Xerophthalmia	1	0	0
		Diplopia	1	0	0
		Visual impairment	3	0	0
		<b>Eye disorders</b>	<b>5</b>	<b>0</b>	<b>0</b>
	Gastrointestinal disorders	Tooth disorder	1	0	1
		Diarrhoea	2	0	0
		Abdominal pain	2	0	1
		Nausea	4	0	3
		Vomiting	2	1	1
		Mouth ulceration	1	0	0
		Dry mouth	1	0	1
		<b>Gastrointestinal disorders</b>	<b>13</b>	<b>1</b>	<b>7</b>
	General disorders and administration site conditions	Pyrexia	1	0	0
		Sudden death	2	2	0
		Asthenia	1	0	0
		Fatigue	1	0	0
		Malaise	1	0	1
		Face oedema	1	0	1
		Oedema	3	0	2
<b>General disorders and administration site conditions</b>		<b>10</b>	<b>2</b>	<b>4</b>	
Hepatobiliary disorders	Hepatitis cholestatic	4	0	2	
	Jaundice	1	0	0	
	Hepatic function abnormal	6	0	1	
	Hepatic failure	1	0	0	
	Hepatitis	1	0	0	
	Hepatocellular injury	1	0	1	
	<b>Hepatobiliary disorders</b>	<b>14</b>	<b>0</b>	<b>4</b>	
Investigations	Weight increased	1	0	0	
	Drug level increased	1	0	0	
	<b>Investigations</b>	<b>2</b>	<b>0</b>	<b>0</b>	
Metabolism and nutrition disorders	Ketosis	1	0	0	
	Obesity	1	0	1	

**Medicine summary -trimipramine (to end January 2009)**

		Case Group	Death Outcomes	Sole		
Reaction Count	Metabolism and nutrition disorders	Dehydration	1	0	0	
		Gout	1	0	1	
		<b>Metabolism and nutrition disorders</b>	<b>4</b>	<b>0</b>	<b>2</b>	
	Musculoskeletal and connective tissue disorders	Bone pain	2	0	1	
		Arthralgia	1	0	1	
		Myalgia	2	0	1	
		<b>Musculoskeletal and connective tissue disorders</b>	<b>5</b>	<b>0</b>	<b>3</b>	
	Nervous system disorders	Subarachnoid haemorrhage	1	1	0	
		Headache	3	0	2	
		Amnesia	1	0	0	
		Dyskinesia	2	0	0	
		Tardive dyskinesia	2	0	2	
		Paralysis	1	0	0	
		Tremor	3	0	1	
		Ataxia	3	0	0	
		Nystagmus	1	0	0	
		Somnolence	2	0	0	
		Dizziness	2	0	1	
		Paraesthesia	1	0	1	
		Ageusia	1	0	0	
		Dysarthria	1	0	0	
		Grand mal convulsion	1	0	1	
		Convulsion	1	1	0	
		<b>Nervous system disorders</b>	<b>26</b>	<b>2</b>	<b>8</b>	
		Psychiatric disorders	Anxiety	3	0	0
			Nervousness	1	0	1
	Confusional state		2	0	0	
	Delirium		1	0	0	
	Hallucination		2	0	2	
	Affect lability		1	0	0	
	Withdrawal syndrome		1	0	1	
	Insomnia		3	0	2	
	Nightmare		1	0	1	
	<b>Psychiatric disorders</b>		<b>15</b>	<b>0</b>	<b>7</b>	
	Renal and urinary disorders	Renal failure acute	1	0	0	
		Urinary retention	2	0	1	
		<b>Renal and urinary disorders</b>	<b>3</b>	<b>0</b>	<b>1</b>	
	Reproductive system and breast disorders	Erectile dysfunction	2	0	1	
		<b>Reproductive system and breast disorders</b>	<b>2</b>	<b>0</b>	<b>1</b>	
	Respiratory, thoracic and mediastinal disorders	Bronchospasm	1	0	0	
		Dyspnoea	1	0	0	

**Medicine summary -trimipramine (to end January 2009)**

		Case Group	Death Outcomes	Sole		
Reaction Count	Respiratory, thoracic and mediastinal disorders	Haemoptysis	1	0	0	
		<b>Respiratory, thoracic and mediastinal disorders</b>	<b>3</b>	<b>0</b>	<b>0</b>	
	Skin and subcutaneous tissue disorders	Periorbital oedema	1	0	1	
		Urticaria	3	0	1	
		Dermatitis bullous	1	0	1	
		Skin discolouration	1	0	1	
		Rash erythematous	3	0	2	
		Photosensitivity reaction	2	0	2	
		Pruritus	3	0	0	
		Rash	3	0	1	
		Rash maculo-papular	1	0	0	
		Acne	1	0	0	
		Alopecia	2	0	1	
		Purpura	1	0	1	
		<b>Skin and subcutaneous tissue disorders</b>	<b>22</b>	<b>0</b>	<b>11</b>	
		Vascular disorders	Hypotension	2	0	0
			Flushing	1	0	1
	<b>Vascular disorders</b>		<b>3</b>	<b>0</b>	<b>1</b>	
	<b>Reaction</b>		<b>133</b>	<b>5</b>	<b>50</b>	